Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.
M A Pfeffer, M Domanski, Y Rosenberg...
https://pubmed.ncbi.nlm.nih.gov/9719019Completed
Phase 3
Age: 50Years - 100Years
All Genders
ID00000558
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-04-15
N/A
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether the addition of angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality and reduce the risk of myocardial infarction.
CONDITIONS
Official Title
Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)
Who Can Participate
Age: 50Years - 100Years
All Genders
Eligibility Criteria
You may qualify if you...
Men and women patients at least 50 years of age with coronary heart disease documented by angiography and a left ventricular ejection fraction of 40 percent or more.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
PREVENTION
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial.
M A Pfeffer, M Domanski, J Verter...
https://pubmed.ncbi.nlm.nih.gov/11526345Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Eugene Braunwald, Michael J Domanski, Sarah E Fowler...
https://pubmed.ncbi.nlm.nih.gov/15531767Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.
Teng Ma, Jian Zhao, Yechao Yan...
https://pubmed.ncbi.nlm.nih.gov/37388640Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes.
John M Lachin, Ionut Bebu
https://pubmed.ncbi.nlm.nih.gov/26336199Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
Jacob A Udell, David A Morrow, Petr Jarolim...
https://pubmed.ncbi.nlm.nih.gov/24727254Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
Torbjørn Omland, Marc A Pfeffer, Scott D Solomon...
https://pubmed.ncbi.nlm.nih.gov/23414791Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.
Scott D Solomon, Julie Lin, Caren G Solomon...
https://pubmed.ncbi.nlm.nih.gov/18025537Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
Scott D Solomon, Madeline M Rice, Kathleen A Jablonski...
https://pubmed.ncbi.nlm.nih.gov/16801465